BioCryst presents real-world data on the effects of ORLADEYO on HAE attacks

BioCryst Pharmaceuticals announced new real-world data demonstrating rapid, sustained reduction of patient-reported HAE attacks and consistently low attack rates among patients 12 years and older who started on oral, once-daily ORLADEYO for the prophylactic treatment of hereditary angioedema, including patients who switched from other prophylactic therapies. The data are being presented at the 2022 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology, ACAAI. BioCryst ACAAI 2022 Presentation Highlights: Consistently Low Hereditary Angioedema Attack Rates Observed with Berotralstat Regardless of Previous Prophylaxis: This analysis assessed patient-reported HAE attack rates of patients on ORLADEYO 110 mg or 150 mg who were previously on another prophylactic therapy. Regardless of prior prophylaxis, a rapid reduction in median attack rates was observed early. The reduction of median attack rates was sustained throughout the 360-day treatment period. Upon initiating ORLADEYO treatment, the reduction in median attack rates from baseline over the 1-360 days period was consistent for patients regardless of their prior prophylaxis therapy. The reductions after starting ORLADEYO for each prior prophylactic therapy were: 77 percent reduction for patients previously on lanadelumab; 64 percent reduction for patients previously on SC C1-INH; 70 percent reduction for patients previously on danazol; and 72 percent reduction previously on IV C1-INH. The incidence of AEs reported was lower than the incidence reported in clinical trials. Rapid and Sustained Reductions in Hereditary Angioedema Attack Rates with Long-term Berotralstat: This analysis assessed the efficacy of ORLADEYO 110 mg or 150 mg in patients for a treatment period of more than 270 days. Patients reported a meaningful reduction in HAE attack rates when treated with ORLADEYO. An 80 percent average reduction from median baseline attack rate was observed during the initial 90-day treatment period.